Skip to content

Study · In vitro (cells) · 2012

10 results

Mechano-growth factor E peptide inhibits the differentiation and mineralization of osteoblasts.

Xin C, Bingbing Z, Yuanliang W, Chengyu X, Li Y, Moyuan D, Qin P, Yuxiao L

Archives of oral biology18 Dec 2011Cited by 15 (Europe PMC)

PMID22186070 (opens in a new tab)DOI10.1016/j.archoralbio.2011.11.016 (opens in a new tab)PepBankPUB-22186070
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

7 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In MC3T3-E1 pre-osteoblasts, MGF-E peptide decreased ALP activity.

    In plain wordsIn cells, the MGF-E peptide lowered a marker of bone cell maturing (ALP activity).

    Peptide
    MGF / PEG-MGF
    Outcome
    DecreaseAlkaline phosphatase (ALP) activity
    Study

    n: not reported in source

    MC3T3-E1 pre-osteoblast line
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1 nMAs given in this study.

    Source sentences

    Summary
    In the MGF-E-treated osteoblasts, ALP activity decreased with increased Erk activation.
    1 context sentence
    Summary · context
    MGF-E (1 nM) peptide was then used to treat the pre-osteoblast line MC3T3-E1.
  2. 02LabIn vitro (cells)Activity measurement

    In MC3T3-E1 pre-osteoblasts, MGF-E peptide treatment increased Erk activation.

    In plain wordsIn cells, the MGF-E peptide raised activity of the Erk signal pathway.

    Peptide
    MGF / PEG-MGF
    Outcome
    IncreaseErk activation
    Study

    n: not reported in source

    MC3T3-E1 pre-osteoblast line
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1 nMAs given in this study.

    Source sentences

    Summary
    In the MGF-E-treated osteoblasts, ALP activity decreased with increased Erk activation.
    1 context sentence
    Summary · context
    MGF-E (1 nM) peptide was then used to treat the pre-osteoblast line MC3T3-E1.
  3. 03LabIn vitro (cells)Activity measurement

    In MC3T3-E1 pre-osteoblasts, MGF-E peptide inhibited the transcription and translation of collagen I.

    In plain wordsIn cells, the MGF-E peptide lowered production of collagen I.

    Peptide
    MGF / PEG-MGF
    Outcome
    DecreaseCollagen I transcription and translation
    Study

    n: not reported in source

    MC3T3-E1 pre-osteoblast line
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1 nMAs given in this study.

    Source sentences

    Summary
    The transcription and translation of Col I were inhibited, but those of OPN were enhanced.
    1 context sentence
    Summary · context
    MGF-E (1 nM) peptide was then used to treat the pre-osteoblast line MC3T3-E1.
  4. 04LabIn vitro (cells)Activity measurement

    In MC3T3-E1 pre-osteoblasts, MGF-E peptide enhanced the transcription and translation of osteopontin (OPN).

    In plain wordsIn cells, the MGF-E peptide raised production of osteopontin.

    Peptide
    MGF / PEG-MGF
    Outcome
    IncreaseOsteopontin transcription and translation
    Study

    n: not reported in source

    MC3T3-E1 pre-osteoblast line
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1 nMAs given in this study.

    Source sentences

    Summary
    The transcription and translation of Col I were inhibited, but those of OPN were enhanced.
    1 context sentence
    Summary · context
    MGF-E (1 nM) peptide was then used to treat the pre-osteoblast line MC3T3-E1.
  5. 05LabIn vitro (cells)Activity measurement

    In MC3T3-E1 pre-osteoblasts, MGF-E alone up-regulated the mRNA and total protein levels of Cbfα-1.

    In plain wordsIn cells, the MGF-E peptide raised the amount of the bone gene switch Cbfα-1.

    Peptide
    MGF / PEG-MGF
    Outcome
    IncreaseCbfa-1 mRNA and total protein
    Study

    n: not reported in source

    MC3T3-E1 pre-osteoblast line
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1 nMAs given in this study.

    Source sentences

    Summary
    Treatment with MGF-E alone up-regulated the mRNA and total protein levels of Cbfα-1
    1 context sentence
    Summary · context
    MGF-E (1 nM) peptide was then used to treat the pre-osteoblast line MC3T3-E1.
  6. 06LabIn vitro (cells)Activity measurement

    In MC3T3-E1 pre-osteoblasts, MGF-E decreased the fraction of activated Cbfα-1 in the nucleus.

    In plain wordsIn cells, the MGF-E peptide lowered the share of active Cbfα-1 inside the cell nucleus.

    Peptide
    MGF / PEG-MGF
    Outcome
    DecreaseActivated Cbfa-1 in the nucleus
    Study

    n: not reported in source

    MC3T3-E1 pre-osteoblast line
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1 nMAs given in this study.

    Source sentences

    Summary
    but decreased the fraction of activated Cbfα-1 in the nucleus.
    1 context sentence
    Summary · context
    MGF-E (1 nM) peptide was then used to treat the pre-osteoblast line MC3T3-E1.
  7. 07LabIn vitro (cells)Activity measurement

    In MC3T3-E1 pre-osteoblasts, MGF-E delayed mineralization, shown by bone nodule staining and calcium concentration analysis.

    In plain wordsIn cells, the MGF-E peptide slowed the build-up of bone mineral.

    Peptide
    MGF / PEG-MGF
    Outcome
    DecreaseMineralization
    Study

    n: not reported in source

    MC3T3-E1 pre-osteoblast line
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1 nMAs given in this study.

    Source sentences

    Summary
    Mineralization was delayed by MGF-E, as shown by the bone nodule staining and calcium concentration analysis.
    1 context sentence
    Summary · context
    MGF-E (1 nM) peptide was then used to treat the pre-osteoblast line MC3T3-E1.

Studies that did not test the peptide alone3

In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking MGF / PEG-MGF.

  1. 08LabNot a test of MGF / PEG-MGF aloneIn vitro (cells)Activity measurement

    In MGF-E-treated MC3T3-E1 cells, the Erk inhibitor PD98059 abolished the inhibitory effect and increased collagen I expression.

    In plain wordsIn cells treated with MGF-E, an Erk blocker removed the drop in collagen I.

    Peptide
    MGF / PEG-MGF
    Outcome
    IncreaseCollagen I expression with PD98059
    Study

    n: not reported in source

    MC3T3-E1 pre-osteoblast line
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    PD98059 abolished the inhibitory effect and increased the expression of Col I, but decreased that of OPN.
    1 context sentence
    Summary · context
    MGF-E (1 nM) peptide was then used to treat the pre-osteoblast line MC3T3-E1.

    In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MGF / PEG-MGF.

  2. 09LabNot a test of MGF / PEG-MGF aloneIn vitro (cells)Activity measurement

    In MGF-E-treated MC3T3-E1 cells, the Erk inhibitor PD98059 decreased osteopontin expression.

    In plain wordsIn cells treated with MGF-E, an Erk blocker lowered osteopontin.

    Peptide
    MGF / PEG-MGF
    Outcome
    DecreaseOsteopontin expression with PD98059
    Study

    n: not reported in source

    MC3T3-E1 pre-osteoblast line
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    PD98059 abolished the inhibitory effect and increased the expression of Col I, but decreased that of OPN.
    1 context sentence
    Summary · context
    MGF-E (1 nM) peptide was then used to treat the pre-osteoblast line MC3T3-E1.

    In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MGF / PEG-MGF.

  3. 10LabNot a test of MGF / PEG-MGF aloneIn vitro (cells)Activity measurement

    In MGF-E-treated MC3T3-E1 cells, the delayed actions of MGF-E were weakened after treatment with PD98059.

    In plain wordsIn cells treated with MGF-E, an Erk blocker weakened the delay in bone mineral build-up.

    Peptide
    MGF / PEG-MGF
    Outcome
    DecreaseDelayed mineralization with PD98059
    Study

    n: not reported in source

    MC3T3-E1 pre-osteoblast line
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    These delayed actions were weakened after treatment with PD98059.
    1 context sentence
    Summary · context
    MGF-E (1 nM) peptide was then used to treat the pre-osteoblast line MC3T3-E1.

    In this study, MGF / PEG-MGF was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MGF / PEG-MGF.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.